Natco Pharma Ltd - 524816 - Closure of Trading Window
Trading Window closure for Board Meeting03-11-2021
03-11-2021
Natco Pharma Ltd - 524816 - Board Meeting Intimation for Board Meeting
NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2021 ,inter alia, to consider and approve to Consider the Unaudited Results for the quarter and half year ended 30th September 2021 and consider second interim dividend for FY 2021-2203-11-2021
Natco Pharma Ltd - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
intimation loss of share certificate26-10-2021
NATCO PHARMA LTD. - 524816 - Shareholding for the Period Ended September 30, 2021
Natco Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click here08-10-2021
Natco Pharma Ltd - 524816 - Statement Of Investor Complaints For The Quarter Ended September 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- M AdinarayanaDesignation :- Company Secretary and Compliance Officer05-10-2021
Natco Pharma Ltd - 524816 - PCS Certificate For Transfer / Transmission/ Transposition
PCS Certificate for Transfer / Transmission/ Transposition for the half year ended September, 202105-10-2021
Natco Pharma Ltd - 524816 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September, 202105-10-2021
Natco Pharma launches Everolimus tablets in the US
The drug is generally indicated for the treatment of certain types of cancer01-10-2021
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO Announces Launch of its 10mg strength for Everolimus Tablets (generic for Afinitor(r)) in the US market01-10-2021
NATCO PHARMA LTD. - 524816 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Natco Pharma Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here30-09-2021